A 58-year-old woman from Mumbai with type 2 diabetes mellitus (HbA1c 8.2%) and hypertension presents for lipid screening. Her lipid panel shows: total cholesterol 280 mg/dL, LDL cholesterol 185 mg/dL, HDL cholesterol 32 mg/dL, and triglycerides 380 mg/dL. She is not on any lipid-lowering therapy. Lipoprotein electrophoresis shows a broad beta band with IDL accumulation. Her fasting glucose is 156 mg/dL. What is the primary lipoprotein abnormality, and what is the genetic basis?

Explanation

## Type III Hyperlipoproteinemia (Dysbetalipoproteinemia) ### Clinical Recognition **Key Point:** The combination of: - Moderately elevated triglycerides (300–500 mg/dL) - Elevated total cholesterol and LDL - **Broad beta band on lipoprotein electrophoresis** (IDL accumulation) - **Tuberoeruptive or palmar xanthomas** (though not mentioned, typical) - Metabolic syndrome features (diabetes, hypertension) ...is diagnostic of Type III hyperlipoproteinemia (familial dysbetalipoproteinemia). ### Genetic Basis **High-Yield:** Type III requires **TWO conditions**: 1. **Genetic predisposition:** apoE2/E2 genotype (impaired hepatic remnant receptor binding) 2. **Metabolic trigger:** Obesity, diabetes, hypothyroidism, or estrogen use that increases VLDL production ### ApoE Isoforms and Remnant Clearance | ApoE Genotype | Remnant Clearance | Lipid Profile | Disease Risk | | --- | --- | --- | --- | | **E3/E3** (wild-type) | Normal | Normal lipids | Baseline | | **E2/E2** | **Impaired** | Dysbetalipoproteinemia (if triggered) | Type III if metabolic stress | | **E2/E3** | Intermediate | Usually normal, rarely Type III | Low risk | | **E3/E4** | Normal | Mildly elevated LDL | Increased CAD risk | | **E4/E4** | Normal | Elevated LDL | Highest CAD risk | **Mnemonic:** **ApoE2 = Remnant Retention** — the E2 isoform binds poorly to hepatic receptors (LDLR and LRP), causing accumulation of chylomicron and VLDL remnants (IDL). ### Pathophysiology of Type III ```mermaid flowchart TD A[ApoE2/E2 Genotype]:::outcome --> B[Impaired Hepatic Remnant Uptake] B --> C[IDL Accumulation in Circulation] C --> D[Broad Beta Band on Electrophoresis] E[Metabolic Trigger: Diabetes/Obesity/Estrogen]:::outcome --> F[Increased VLDL Production] F --> G[More Remnants Generated] G --> C C --> H[Elevated Triglycerides 300-500 mg/dL]:::action C --> I[Elevated LDL + Total Cholesterol]:::action H --> J[Xanthomas: Tuberoeruptive, Palmar]:::outcome I --> K[High CAD Risk]:::urgent ``` ### Diagnostic Criteria for Type III **Key Point:** Diagnosis requires lipoprotein electrophoresis or ultracentrifugation showing **IDL accumulation** (broad beta band), not just lipid values. | Feature | Type III | Type IIb | Type IV | | --- | --- | --- | --- | | **Triglycerides** | 300–500 | 200–400 | 200–500 | | **Total Cholesterol** | Elevated | Elevated | Mildly elevated | | **LDL** | Elevated | Elevated | Normal | | **HDL** | Low | Low | Low | | **Electrophoresis** | **Broad beta (IDL)** | Normal or beta ↑ | Beta normal | | **Genetic Basis** | ApoE2/E2 + trigger | Polygenic | Polygenic | | **Xanthomas** | Tuberoeruptive, palmar | Tendon | Rare | | **Age of Onset** | 30–50 years | Variable | Variable | ### Clinical Features **Clinical Pearl:** Type III is one of the few dyslipidemias with **pathognomonic xanthomas**: - **Tuberoeruptive xanthomas:** Yellow nodules on elbows, knees, buttocks (overlapping with Type I) - **Palmar xanthomas:** Yellow discoloration of palms and finger creases (highly specific for Type III) ### Management 1. **Fibrates:** First-line (very effective at reducing triglycerides and IDL) 2. **Statins:** Reduce LDL and total cholesterol 3. **Lifestyle:** Weight loss, diabetes control, avoid estrogens 4. **Target:** LDL <100 mg/dL, triglycerides <150 mg/dL **High-Yield:** Fibrates are dramatically more effective in Type III than in other hypertriglyceridemias because they directly reduce VLDL production and increase remnant clearance. ### Why This Case Is Type III 1. **Broad beta band on electrophoresis** → IDL accumulation (diagnostic) 2. **Triglycerides 300–400 mg/dL** → typical range for Type III 3. **Elevated LDL and total cholesterol** → remnant accumulation 4. **Metabolic syndrome (diabetes, hypertension)** → triggers Type III in apoE2/E2 carriers 5. **Age 58, female** → typical presentation age 6. **ApoE2/E2 genotype implied** → required for Type III diagnosis